{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:53:38Z","timestamp":1790391218930,"version":"4.1.0"},"reference-count":91,"publisher":"Informa UK Limited","issue":"10","license":[{"start":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T00:00:00Z","timestamp":1726704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Hong Kong Research Grant Council Earmarked Research","award":["14108923"],"award-info":[{"award-number":["14108923"]}]},{"name":"Charlie Lee Precision Immuno-oncology program"},{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2024,10,2]]},"DOI":"10.1080\/13543784.2024.2401910","type":"journal-article","created":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:32:03Z","timestamp":1726763523000},"page":"1019-1028","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Progress in the clinical development of investigational systemic agents for recurrent and metastatic nasopharyngeal carcinoma"],"prefix":"10.1080","volume":"33","author":[{"given":"Kelvin","family":"Yan","sequence":"first","affiliation":[{"name":"State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren Wt","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, National Cancer Centre Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigette B.B.Y.","family":"Ma","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,9,19]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13688-7"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00524-x"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)31388-5"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.014"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-017-0503-7"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.20792"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-007-0575-8"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S58791"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-015-0011-0"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.147"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz020"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2012.01.004"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2009.01292.x"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-012-9896-5"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-015-0264-0"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.49392"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14121"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010330"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.462"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.254"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09784"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4036"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2010.64"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.11.062"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgt165"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.2.7"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30451-4"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30441-1"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.2304"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12319"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/abbs\/gmp025"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26201-1"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01763-z"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2854"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31023"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-023-01101-3"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/hed.21877"},{"issue":"8","key":"e_1_3_5_42_1","first-page":"2595","article-title":"Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival","volume":"8","author":"Hui EP","year":"2002","unstructured":"Hui EP, Chan AT, Pezzella F, et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res. 2002;8(8):2595\u20132604.","journal-title":"Clin Cancer Res"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00486"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2871"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-3409"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8584"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-0652"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17264"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-1667"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013635"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.63.5995"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab076"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-03140-x"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100313"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102136"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"issue":"10","key":"e_1_3_5_57_1","first-page":"4622","article-title":"Recombinant human endostatin injection (endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study","volume":"12","author":"Xu L","year":"2022","unstructured":"Xu L, Li D, Ji J, et al. Recombinant human endostatin injection (endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study. Am J Cancer Res. 2022;12(10):4622\u20134636.","journal-title":"Am J Cancer Res"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02790-1"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1312240"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31279"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3675"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.007"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0388"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1238"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0822"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30495-9"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02712"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000437"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104640"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100617"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38407-7"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6855"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00411-4"},{"issue":"2","key":"e_1_3_5_74_1","first-page":"A466","article-title":"436\u2005436\u2005A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy","volume":"9","author":"Mai H","year":"2021","unstructured":"Mai H, Lin S, Chen D, et al. 436\u2005436\u2005A phase II study of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy. J Immunother Cancer. 2021;9(Suppl 2):A466.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_5_75_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965"},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02162-w"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.106083"},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01640-9"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1319"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00049-9"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108330"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40402-x"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1298418"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102043"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2022.07.009"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.776"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028485"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2006"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2024.2401910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T05:05:46Z","timestamp":1729573546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2024.2401910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,19]]},"references-count":91,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,2]]}},"alternative-id":["10.1080\/13543784.2024.2401910"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2024.2401910","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}